Literature DB >> 15823098

Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer.

A Du Bois1, J Rochon, C Lamparter, J Pfisterer.   

Abstract

The purpose of this study was to evaluate the pattern and quality of care for ovarian cancer in Germany and analyze prognostic factors with emphasis on characteristics of treating institutions, hospital volume, and participation in clinical trials. This study utilized national survey including patients with histologically proven invasive epithelial ovarian cancer diagnosed in the third quarter of 2001 including descriptive analysis of pattern of surgical care and systemic treatment in early (FIGO I-IIA) and advanced (FIGO IIB-IV) ovarian cancer and both univariate and multivariate analysis of prognostic factors. One third of all patients diagnosed in the third quarter of 2001 in Germany, 476 patients, were included. Standard care according to German guidelines was provided to only 35.5% of patients with early ovarian cancer. Recommended chemotherapy was given to 78% in advanced disease. Multivariate analysis showed advanced stage, poor performance status, comorbidity, ascites, and treatment in an institution not participating in cooperative studies to be associated with inferior survival. Non-participation was associated with an 82% increase of risk (HR = 1.82; 95% CI, 1.27-2.61; P= 0.001). Hospital volume did not affect treatment outcome. Adherence to treatment guidelines showed remarkable variety among German hospitals, indicating options and need for improvement. Selecting an institution that participates in cooperative trials might be an option for individual patients seizing the chance for better quality of care even when individual factors might hamper enrollment in a study.

Entities:  

Mesh:

Year:  2005        PMID: 15823098     DOI: 10.1111/j.1525-1438.2005.15202.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  29 in total

1.  Primary care research after the Act: why commissioners and academia need to work together.

Authors:  Peter Brindle
Journal:  Br J Gen Pract       Date:  2012-05       Impact factor: 5.386

2.  [Clinical network structures in uro-oncology. A model for the future?].

Authors:  A Heidenreich; F Finke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

3.  Barriers and challenges to global clinical cancer research.

Authors:  Bostjan Seruga; Aleksander Sadikov; Eduardo L Cazap; Lucia Beatriz Delgado; Raghunadharao Digumarti; Natasha B Leighl; Mohamed M Meshref; Hironobu Minami; Eliezer Robinson; Nise Hitomi Yamaguchi; Doug Pyle; Tanja Cufer
Journal:  Oncologist       Date:  2013-12-09

4.  Barriers to Cancer Clinical Trial Participation Among Saudi Nationals: A Cross-Sectional Study.

Authors:  Khalid M Almutairi; Wadi B Alonazi; Abdulaziz A Alodhayani; Jason M Vinluan; Mahaman Moussa; Abdulrahman S Al-Ajlan; Khalid Alsaleh; Duna Alruwaimi; Nader E Alotaibi
Journal:  J Relig Health       Date:  2017-04

5.  Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'

Authors:  Christian Jackisch; Michael Untch; Dimitrios Chatsiproios; Christiane Lamparter; Friedrich Overkamp; Werner Lichtenegger; Wolfgang Rönsberg; Christoph Thomssen; Gunter von Minckwitz; Ute-Susann Albert
Journal:  Breast Care (Basel)       Date:  2008-04-25       Impact factor: 2.860

6.  The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Authors:  Bruno C Medeiros; Megan Othus; Martin S Tallman; Zhuoxin Sun; Hugo F Fernandez; Jacob M Rowe; Hillard M Lazarus; Frederick R Appelbaum; Selina M Luger; Mark R Litzow; Harry P Erba
Journal:  Leuk Res       Date:  2019-01-17       Impact factor: 3.156

7.  Paediatric patient family engagement with clinical research at a tertiary care paediatric hospital.

Authors:  Carson Gill; Mark J Ansermino; Shubhayan Sanatani; Kishore Mulpuri; Quynh Doan
Journal:  Paediatr Child Health       Date:  2014-12       Impact factor: 2.253

8.  Impact of cardiovascular comorbidity on ovarian cancer mortality.

Authors:  Eileen H Shinn; Daniel J Lenihan; Diana L Urbauer; Karen M Basen-Engquist; Alan Valentine; Laura Palmero; Myrshia L Woods; Pooja Patel; Alpa M Nick; Mian M K Shahzad; Rebecca L Stone; Antoinette Golden; Emma Atkinson; Susan K Lutgendorf; Anil K Sood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

9.  Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system?

Authors:  Britney Jones; Rachel Syme; Misha Eliasziw; Bernhard J Eigl
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

10.  Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.

Authors:  Bree R Eaton; Stephanie L Pugh; Jeffrey D Bradley; Greg Masters; Vivek S Kavadi; Samir Narayan; Lucien Nedzi; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Douglas W Johnson; Joanne Meng; Walter J Curran
Journal:  J Natl Cancer Inst       Date:  2016-05-19       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.